Accéder au contenu
Merck

Antimicrobial spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate.

American journal of hospital pharmacy (1981-07-01)
F D Pien, P W Ho
RÉSUMÉ

The antibiotic spectrum, pharmacology, adverse effects, and therapeutic use of amikacin sulfate are reviewed. Amikacin, a semisynthetic analog of kanamycin, is highly active against most gram-negative bacteria including many gentamicin-resistant strains. Amikacin's pharmacologic properties have been studied extensively in both children and adults. It achieves high, predictable, and prolonged blood concentrations with a favorable therapeutic index. Amikacin does cause nephrotoxicity and ototoxicity; however there is no conclusive evidence that these toxicities differ from those caused by other major aminoglycosides. The effectiveness of amikacin sulfate in the treatment of serious gram-negative bacillary infections is well documented. Amikacin sulfate is an important addition to the antibiotic armamentarium of a hospital with high gentamicin or tobramycin resistance. In hospitals without substantial aminoglycoside resistance, its use is debatable because amikacin has not been shown to have increased clinical efficacy compared with the other aminoglycosides for infections caused by susceptible bacteria.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Amikacin hydrate, aminoglycoside antibiotic
Sigma-Aldrich
Amikacin disulfate salt, potency: 674-786 μg per mg (as amikacin base)
Amikacin, European Pharmacopoeia (EP) Reference Standard
Amikacin sulfate, European Pharmacopoeia (EP) Reference Standard
Amikacin for system suitability, European Pharmacopoeia (EP) Reference Standard